Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

61. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. IMPORTANCE: Additional therapies are needed for prevention of osteoporotic fractures. Abaloparatide is a selective activator of the parathyroid hormone type 1 receptor. OBJECTIVE: To determine the efficacy and safety of abaloparatide, 80 μg, vs placebo for prevention of new vertebral fracture in postmenopausal women at risk of osteoporotic fracture. DESIGN (...) placebo. The Kaplan-Meier estimated event rate for nonvertebral fracture was lower with abaloparatide vs placebo. BMD increases were greater with abaloparatide than placebo (all P < .001). Incidence of hypercalcemia was lower with abaloparatide (3.4%) vs teriparatide (6.4%) (risk difference [RD], −2.96 [95%CI, −5.12 to −0.87]; P = .006). [table: see text]. CONCLUSIONS AND RELEVANCE: Among postmenopausal women with osteoporosis, the use of subcutaneous abaloparatide, compared with placebo, reduced

JAMA2016 Full Text: Link to full Text with Trip Pro

62. [Systematic guideline search and appraisal, as well as extraction of relevant recommendations, for a DMP "osteoporosis"]

[Systematic guideline search and appraisal, as well as extraction of relevant recommendations, for a DMP "osteoporosis"] Systematische leitlinienrecherche und -bewertung sowie extraktion relevanter empfehlungen für ein DMP osteoporose: abschlussbericht; auftrag V14-0 [Systematic guideline search and appraisal, as well as extraction of relevant recommendations, for a DMP "osteoporosis"] Systematische leitlinienrecherche und -bewertung sowie extraktion relevanter empfehlungen für ein DMP (...) osteoporose: abschlussbericht; auftrag V14-0 [Systematic guideline search and appraisal, as well as extraction of relevant recommendations, for a DMP "osteoporosis"] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen

Health Technology Assessment (HTA) Database.2016

63. Alendronic Acid / Colecalciferol Mylan - postmenopausal osteoporosis in women at risk of vitamin D deficiency

Alendronic Acid / Colecalciferol Mylan - postmenopausal osteoporosis in women at risk of vitamin D deficiency 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 24 June 2016 EMA/354096/2016 EMEA/H/C/004172 Questions and answers (...) Withdrawal of the marketing authorisation application for Alendronic Acid/Colecalciferol Mylan (alendronic acid and colecalciferol) On 27 May 2016, Mylan SAS officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Alendronic Acid/Colecalciferol Mylan, for the treatment of postmenopausal osteoporosis in women at risk of vitamin D deficiency. What is Alendronic Acid/Colecalciferol Mylan? Alendronic Acid

European Medicines Agency - EPARs2016

64. Diagnosis and Management of Osteoporosis

Diagnosis and Management of Osteoporosis DIAGNOSIS AND MANAGEMENT OF OSTEOPOROSIS Clinical Practice Guideline | February 2016 These recommendations are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. They should be used as an adjunct to sound clinical decision making. OBJECTIVE Alberta clinicians will understand who and how to screen, assess, diagnose, treat and manage osteoporosis (...) and/or fracture risk. TARGET POPULATION All men and women 50 years of age and older EXCLUSIONS All men and women under 50 years of age This guideline is partially adapted from Papaioannou A, Morin S, Cheung AM, et al; for the Scientific Advisory Council of Osteoporosis Canada. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: Summary. CMAJ. 2010;182:1864-73. 1 KEY MESSAGES ? The goal is to find patients at high risk of fracture, not just low bone mineral density

Toward Optimized Practice2016

65. Postmenopausal Osteoporosis.

Postmenopausal Osteoporosis. Postmenopausal Osteoporosis. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27223157 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add (...) to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 May 26;374(21):2096-7. doi: 10.1056/NEJMc1602599. Postmenopausal Osteoporosis. , . Comment on [N Engl J Med. 2016] [N Engl J Med. 2016] [N Engl J Med. 2016] [N Engl J Med. 2016] PMID: 27223157 DOI: [Indexed for MEDLINE] Free full text Publication types MeSH terms Substances Full Text Sources Medical PubMed Commons 0 comments How to cite this comment: Supplemental Content

NEJM2016 Full Text: Link to full Text with Trip Pro

66. Postmenopausal Osteoporosis.

Postmenopausal Osteoporosis. Postmenopausal Osteoporosis. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27223158 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add (...) to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 May 26;374(21):2095. doi: 10.1056/NEJMc1602599#SA1. Postmenopausal Osteoporosis. 1 , 2 . 1 Uppsala University, Uppsala, Sweden karl.michaelsson@surgsci.uu.se. 2 Linköping University, Linköping, Sweden. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2016] PMID: 27223158 PMCID: DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Grant support Full

NEJM2016 Full Text: Link to full Text with Trip Pro

67. Postmenopausal Osteoporosis.

Postmenopausal Osteoporosis. Postmenopausal Osteoporosis. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27223159 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add (...) to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 May 26;374(21):2095-6. doi: 10.1056/NEJMc1602599#SA2. Postmenopausal Osteoporosis. 1 . 1 University of Washington, Seattle, WA smott@uw.edu. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2016] PMID: 27223159 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical PubMed Commons 0 comments How to cite this comment

NEJM2016 Full Text: Link to full Text with Trip Pro

68. Postmenopausal Osteoporosis.

Postmenopausal Osteoporosis. Postmenopausal Osteoporosis. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27223160 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add (...) to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 May 26;374(21):2096. doi: 10.1056/NEJMc1602599#SA3. Postmenopausal Osteoporosis. 1 , 2 , 3 ; . 1 University of Toronto, Toronto, ON, Canada angela.cheung@uhn.ca. 2 McMaster's University, Hamilton, ON, Canada. 3 McGill University, Montreal, QC, Canada. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2016] PMID: 27223160 DOI: [Indexed for MEDLINE] Publication types

NEJM2016 Full Text: Link to full Text with Trip Pro

69. Relationships between serum Omentin-1 levels and bone mineral density in older men with osteoporosis

Relationships between serum Omentin-1 levels and bone mineral density in older men with osteoporosis 29063025 2018 11 13 2095-882X 2 1 2016 Mar Chronic diseases and translational medicine Chronic Dis Transl Med Relationships between serum Omentin-1 levels and bone mineral density in older men with osteoporosis. 48-54 10.1016/j.cdtm.2016.02.003 To investigate the correlation between serum Omentin-1 levels and the presence of osteoporosis in older men. Serum Omentin-1, bone turnover biochemical (...) markers, and bone mineral density (BMD) were determined in 45 older men with osteoporosis or 45 older men without osteoporosis (65-70 years old). Omentin-1 levels were increased in older men with osteoporosis, and the differences remained significant after controlling for fat mass. Omentin-1 was negatively correlated with BMD. In a multiple linear stepwise regression analysis, Omentin-1, lean mass, but not fat mass, were independent predictors of BMD for the combined group. Significant negative

Chronic diseases and translational medicine2016 Full Text: Link to full Text with Trip Pro

70. Alendronic acid (Binosto) - Treatment of postmenopausal osteoporosis

Alendronic acid (Binosto) - Treatment of postmenopausal osteoporosis Published 11 April 2016 Product Update: alendronic acid 70mg effervescent tablet (Binosto ® ) SMC No.(1137/16) Internis Pharmaceuticals Ltd 04 March 2016 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission (...) alendronic acid effervescent tablets (Binosto ® ) is accepted for restricted use within NHS Scotland. Indication under review: Treatment of postmenopausal osteoporosis. SMC restriction: for use in patients who are unable to swallow tablets where alendronic acid is the appropriate treatment choice. Alendronic acid 70mg effervescent tablets have demonstrated bioequivalence to alendronic acid 70mg tablets. The effervescent tablet formulation provides an alternative for patients who cannot swallow tablets

Scottish Medicines Consortium2016

71. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis

American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis ENDOCRINE PRACTICE Vol 22 (Suppl 4) September 2016 1 AACE/ACE Guidelines AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS — 2016 Pauline M. Camacho, MD, FACE; Steven M. Petak, MD, MACE (...) University Osteoporosis and Metabolic Bone Disease Center, Chicago, IL; 2 Associate Clinical Professor Weill-Cornell Medical College, Division Head Endocrinology and Chief of Endocrinology, Houston Methodist Hospital, Houston, TX; 3 School of Medicine and Public Health, University of Wisconsin, Madison, WI; 4 Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN; 5 Clinical Professor of Medicine, University of California, San Francisco; 6 Division of Endocrinology

American Association of Clinical Endocrinologists2016

72. Osteoporosis - prevention of fragility fractures

Osteoporosis - prevention of fragility fractures Osteoporosis - prevention of fragility fractures - NICE CKS Clinical Knowledge Summaries Share Osteoporosis - prevention of fragility fractures - Summary Osteoporosis is a disease characterized by low bone mass and structural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. Osteoporosis itself is asymptomatic and often remains undiagnosed until a fragility fracture occurs. An osteoporotic (...) fracture is a fragility fracture occurring as a consequence of increased bone fragility caused by osteoporosis. Characteristically fractures occur in the wrist, spine, and hip. A fragility fracture is defined as a fracture following a fall from standing height or less, although vertebral fractures may occur spontaneously, or as a result of routine activities. In England and Wales, it is estimated that annually around 180,000 fractures occur as a result of osteoporosis. Risk factors for osteoporosis

NICE Clinical Knowledge Summaries2016

73. Osteoporosis and Bone Mineral Density

Osteoporosis and Bone Mineral Density Date of origin: 1998 Last review date: 2016 ACR Appropriateness Criteria ® 1 Osteoporosis and Bone Mineral Density American College of Radiology ACR Appropriateness Criteria ® Clinical Condition: Osteoporosis and Bone Mineral Density Variant 1: Asymptomatic BMD screening or individuals with established or clinically suspected low BMD. 1. All women age 65 years and older and men age 70 years and older (asymptomatic screening) 2. Women younger than age 65 (...) years who have additional risk for osteoporosis, based on medical history and other findings. Additional risk factors for osteoporosis include: a. Estrogen deficiency b. A history of maternal hip fracture that occurred after the age of 50 years c. Low body mass ( 1 year before age 42 years) 3. Women younger than age 65 years or men younger than age 70 years who have additional risk factors, including: a. Current use of cigarettes b. Loss of height, thoracic kyphosis 4. Individuals of any age

American College of Radiology2016

74. Management of osteoporosis and the prevention of fragility fractures

Management of osteoporosis and the prevention of fragility fractures SIGN 142 • Management of osteoporosis and the prevention of fragility fractures A national clinical guideline March 2015 EvidenceKEY TO EVIDENCE STATEMENTS AND RECOMMENDATIONS LEVELS OF EVIDENCE 1 ++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1 + Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 1 - Meta-analyses, systematic reviews, or RCTs (...) is the definitive version at all times. This version can be found on our web site www.sign.ac.uk. This document is produced from elemental chlorine-free material and is sourced from sustainable forests.Scottish Intercollegiate Guidelines Network Management of osteoporosis and the prevention of fragility fractures A national clinical guideline March 2015Scottish Intercollegiate Guidelines Network Gyle Square, 1 South Gyle Crescent Edinburgh EH12 9EB www.sign.ac.uk First published March 2015 ISBN 978 1 909103 35

SIGN2015

75. High-Protein Diet Without Increased Calcium Intake Can Lead to Ridge Resorption and Osteoporosis in Women

High-Protein Diet Without Increased Calcium Intake Can Lead to Ridge Resorption and Osteoporosis in Women UTCAT2893, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title High-Protein Diet Without Increased Calcium Intake Can Lead to Ridge Resorption and Osteoporosis in Women Clinical Question How does a high protein diet affect ridge resorption in women? Clinical Bottom Line A high protein diet coupled with a low calcium (...) intake can increase urinary losses of calcium and is linked to osteoporosis and ridge resorption in older women. This is supported by narrative reviews outlining observations of populations who maintain a high protein diet and a narrative review of studies showing the relationship between increased protein intake and increased levels of calcium lost in urine. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence

UTHSCSA Dental School CAT Library2015

76. Repeat Dual Energy X-Ray Absorptiometry Intervals in Osteoporosis

Repeat Dual Energy X-Ray Absorptiometry Intervals in Osteoporosis Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered (...) in Osteoporosis: Clinical Effectiveness and Guidelines DATE: 04 March 2015 RESEARCH QUESTIONS 1. What are the clinical benefits and harms of repeat dual energy x-ray absorptiometry (DEXA) scans every two years in patients with osteoporosis or at risk for osteoporosis? 2. What are the evidence-based guidelines for DEXA in patients with osteoporosis or at risk for osteoporosis? KEY FINDINGS Two health technology assessments, one observational study, and eight evidence-based guidelines were identified regarding

Canadian Agency for Drugs and Technologies in Health - Rapid Review2015

77. Cross-sectional study: An online system shows promise for the early detection of osteoporosis in Asian women

Cross-sectional study: An online system shows promise for the early detection of osteoporosis in Asian women An online system shows promise for the early detection of osteoporosis in Asian women | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here An online system shows promise for the early detection of osteoporosis in Asian women Article Text Adult nursing Cross-sectional study An online system shows promise for the early detection of osteoporosis in Asian women Carl M Harper Statistics from Altmetric.com No Altmetric data available for this article. Commentary

Evidence-Based Nursing (Requires free registration)2015

78. Cholecalciferol 25,000 international units oral solution (InVita D3) - osteoporosis in patients with vitamin D deficiency or at risk of vitamin D insufficiency

Cholecalciferol 25,000 international units oral solution (InVita D3) - osteoporosis in patients with vitamin D deficiency or at risk of vitamin D insufficiency Publication 08 December 2014 Product Update: cholecalciferol 25,000 international units oral solution (InVita D3 ® ) SMC No. (1011/14) Consilient Health Limited 07 November 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs (...) ) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission cholecalciferol oral solution (InVita D3 ® ) is accepted for use within NHS Scotland. Indication under review: the prevention and treatment of vitamin D deficiency. As an adjunct to specific therapy for osteoporosis in patients with vitamin D deficiency or at risk of vitamin D insufficiency. The therapeutic use and safety profile of cholecalciferol as a treatment for vitamin D deficiency

Scottish Medicines Consortium2014

79. Denosumab (Prolia) - osteoporosis in men at increased risk of fractures

Denosumab (Prolia) - osteoporosis in men at increased risk of fractures Published 10 November 2014 Statement of Advice: denosumab (Prolia ® ) 60 mg solution for injection in a pre-filled syringe (No: 1013/14) Amgen Ltd 10 October 2014 ADVICE: in the absence of a submission from the holder of the marketing authorisation denosumab (Prolia ® ) is not recommended for use within NHS Scotland. Indication under review: osteoporosis in men at increased risk of fractures The holder of the marketing

Scottish Medicines Consortium2014

80. Abaloparatide for postmenopausal osteoporosis ? first and second line

Abaloparatide for postmenopausal osteoporosis ? first and second line Abaloparatide for postmenopausal osteoporosis – first and second line Abaloparatide for postmenopausal osteoporosis – first and second line NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Abaloparatide for postmenopausal osteoporosis – first (...) and second line. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Osteoporosis, Postmenopausal Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Centre, School of Health&Population Sciences, University of Birmingham, Public Health building, Edgbaston, Birmingham, B15 2TT

Health Technology Assessment (HTA) Database.2014